Table 1.

Eligibility criteria.

	Inclusion	Exclusion
Population:	Adults with histologically confirmed unresectable NSCLC (stages IIIA, IIIB, and IV)	Adults with NSCLC stage I–II or SCLC
Interventions:	PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, durvalumab) as: monotherapy combination of two or more combination therapy with targeted therapy combination therapy with chemotherapy	Other treatments
Comparators:	Chemotherapy Targeted therapy small molecule inhibitors for EGFR, ROS1, ALK, and MET Placebo Best Supportive Care	Other treatment, no treatment
Outcomes:	Progression-free survival Overall survival Overall adverse events (any cause, treatment related) Serious adverse events (any cause, treatment related)	Other outcomes
Study design:	Randomized controlled trial	All other study designs
Publication language:	English German	Other languages
Search period:	2000–beginning of search	Before 2000

Abbreviations: ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor receptor; MET = mesenchymal–epithelial transition factor; NSCLC = non–small cell lung cancer; PD-1 = programmed cell death protein-1; PD-L1 = programmed cell death ligand-1; ROS1 = proto-oncogene tyrosine-protein kinase; SCLC = small cell lung cancer